Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial read-outs, shelf registrations, and sudden capital raises make Bicara Therapeutics’ SEC disclosures anything but straightforward. If you have ever searched a 300-page prospectus just to find cash-runway details, you know the challenge.
Our platform solves that problem. Stock Titan’s AI instantly converts dense language into plain-English highlights, letting you understand Bicara Therapeutics SEC documents with AI instead of slogging through technical jargon. Need the latest 8-K material events explained or the most recent Bicara Therapeutics quarterly earnings report 10-Q filing? Every form appears here in real time, tagged and summarized.
Here’s how analysts, portfolio managers, and biotech followers use this page:
- Track Bicara Therapeutics insider trading Form 4 transactions and receive alerts on executive stock transactions Form 4 moments after they hit EDGAR.
- Compare R&D spend, dilution risk, and cash burn with our AI-layered Bicara Therapeutics annual report 10-K simplified notes.
- Dive into pipeline progress via Bicara Therapeutics 8-K material events explained, including interim data disclosures for ficerafusp alfa.
- Review compensation packages through the Bicara Therapeutics proxy statement executive compensation section without hunting across exhibits.
Whether you’re screening biotech investments or verifying a single clinical milestone, our comprehensive coverage—10-K, 10-Q, S-1, 8-K, and Bicara Therapeutics Form 4 insider transactions real-time—keeps you ahead of market-moving details. No more page-count anxiety; the insights you need are surfaced instantly, ready for decisive action.
Bicara Therapeutics Inc. is launching an at-the-market offering of up to $150,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on The Nasdaq Global Market under the symbol BCAX, in negotiated transactions or other methods deemed to be at-the-market offerings, with TD Cowen earning a commission of up to 3.0% of gross proceeds.
Bicara is a clinical-stage biopharmaceutical company focused on bifunctional antibodies for solid tumors. Its lead program, ficerafusp alfa, is in a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma, following Phase 1/1b data showing a 54% objective response rate and 21.3‑month median overall survival in an efficacy-evaluable HPV‑negative population. Net proceeds are expected to support research and clinical development, commercialization preparation, expansion of R&D programs, and general corporate purposes.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Financial Officer on Form 4. On November 21, 2025, the CFO exercised 605 stock options at
Bicara Therapeutics Inc. insider transaction: On 11/21/2025, a reporting person who is both a director and the President and COO of Bicara Therapeutics Inc. (BCAX) exercised a stock option for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold shares of common stock on the same day.
The insider reported selling 8,000 shares of common stock at a weighted average price of $18.047 per share and an additional 4,500 shares at the same weighted average price, executed in multiple trades between $18.00 and $18.14. After these transactions, the insider beneficially owned 193,641 shares of common stock directly and 149,334 stock options. The option for 8,000 shares was granted on August 8, 2023 and vests in sixteen equal quarterly installments, contingent on continued service, and was exercised under a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX)41,163 shares of common stock at an exercise price of $3.7898 per share and then sold 41,163 shares of common stock at a weighted average price of $18.8623 per share under transaction code "S".
The option exercised is a stock option (right to buy) covering 41,163 shares of common stock, with an exercise price of $3.7898, expiring on 08/08/2033. The filing states that these option shares vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service. After the reported transactions, the reporting person beneficially owns 309,892 shares of common stock and 236,107 stock options, all held directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Medical Officer, who filed a Form 4 as a single reporting person. On 11/24/2025 and 11/25/2025, the officer exercised stock options to acquire common shares at an exercise price of $3.7898 per share and sold the same number of shares on each corresponding date.
On 11/24/2025, 5,500 shares of common stock were acquired through an option exercise and 5,500 shares were sold at $18.45 per share, leaving 35,497 shares owned directly. On 11/25/2025, additional option exercises and sales covered 4,594 and 906 shares, with sales at a weighted average price of $18.8424. After these transactions, the officer directly owned 35,497 common shares and held stock options covering 69,413 shares, subject to the vesting schedules described.
The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on February 12, 2025, with certain sale prices reported as weighted averages across multiple individual transactions.
Bicara Therapeutics (BCAX) reported Q3 2025 results with a net loss of
Cash, cash equivalents and investments were
Management states existing liquidity is expected to fund operations into the first half of 2029. As a subsequent event, Bicara filed a Form S-3 shelf for up to
Bicara Therapeutics (BCAX)
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities. BCAX common stock trades on The Nasdaq Global Market.
Bicara Therapeutics (BCAX) CEO reported a Form 4 for transactions on October 16, 2025. The executive exercised 24,103 stock options at $3.7898 per share and sold 24,103 common shares at a $18.8259 weighted average price, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the reporting person beneficially owns 309,892 common shares directly and 277,270 derivative securities (options) remain beneficially owned. The sale price ranged from $18.73 to $19.17. The option underlying the exercised shares vests in sixteen equal quarterly installments following August 8, 2023.
Bicara Therapeutics (BCAX) reported insider transactions by its President & COO (also a Director) on 10/15/2025. The officer exercised a stock option for 8,000 shares at an exercise price of $3.7898 and then sold 8,000 shares and an additional 4,500 shares at a weighted average price of $18.1554 (sales occurred between $18.00 and $18.34), executed pursuant to a Rule 10b5‑1 trading plan adopted on February 12, 2025.
Following these transactions, the reporting person beneficially owned 198,141 shares of common stock directly and held 157,334 derivative securities (stock options). The reported option was granted with a term through 08/08/2033 and vests in sixteen equal quarterly installments following 08/08/2023, subject to continued service.
Bicara Therapeutics (BCAX): CEO Form 4 activity. On
FAQ
What is the current stock price of Bicara Therapeutics (BCAX)?
What is the market cap of Bicara Therapeutics (BCAX)?
